^
over4years
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. (PubMed, Br J Cancer)
At the RP2D (40 mg Q8h), TSR-011 demonstrated a favourable safety profile with acceptable QTc changes. Limited clinical activity was observed. Based on the competitive ALK inhibitor landscape and benefit/risk considerations, further TSR-011 development was discontinued.
Clinical • P1 data • Journal
|
ALK (Anaplastic lymphoma kinase)
|
belizatinib (TSR-011)